EICHOR
● Recruiting
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
Condition: Type 2 Diabetes Mellitus · Sponsor: AstraZeneca
About this study
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
This description comes directly from the study's public registry record.
Talk to the study team
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
Locations (150)
| Research Site | Birmingham, Alabama, United States | Not Yet Recruiting |
| Research Site | Daphne, Alabama, United States | Not Yet Recruiting |
| Research Site | Lomita, California, United States | Not Yet Recruiting |
| Research Site | Los Alamitos, California, United States | Not Yet Recruiting |
| Research Site | San Diego, California, United States | Suspended |
| Research Site | Walnut Creek, California, United States | Suspended |
| Research Site | Englewood, Colorado, United States | Not Yet Recruiting |
| Research Site | Bridgeport, Connecticut, United States | Not Yet Recruiting |
| Research Site | Jacksonville, Florida, United States | Not Yet Recruiting |
| Research Site | Orlando, Florida, United States | Not Yet Recruiting |
| Research Site | Conyers, Georgia, United States | Not Yet Recruiting |
| Research Site | Decatur, Georgia, United States | Not Yet Recruiting |
+ 138 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07662044